Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SGMT
SGMT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SGMT News
Sagimet Stock Increases Following Acne Treatment Success
Feb 03 2026
Barron's
Guggenheim Initiates Buy on Sagimet Biosciences with Blockbuster Potential
Feb 03 2026
seekingalpha
Sagimet Biosciences Shares Drop 9% Following Partner's Trial Data Release
Jan 29 2026
seekingalpha
Ascletis' Denifanstat Receives Approval for Acne Treatment
Jan 29 2026
PRnewswire
Ascletis' Denifanstat Receives Approval for Acne Treatment
Jan 29 2026
Newsfilter
CancerVAX Appoints Dr. George Kemble as Senior Scientific Advisor
Jan 27 2026
Yahoo Finance
China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%
Jan 09 2026
NASDAQ.COM
Sagimet Biosciences Advances F4 MASH Combination Therapy Development
Dec 18 2025
Newsfilter
Sagimet Gains Momentum with Licensing Agreement Aimed at Madrigal Drug through Teva Unit
Dec 17 2025
SeekingAlpha
Sagimet Secures Global Exclusive License from TAPI for Resmetirom API
Dec 17 2025
Newsfilter
Sagimet Partners with Ascletis as Acne Drug Denifanstat Receives China Approval
Dec 10 2025
Globenewswire
Sagimet and Ascletis Collaborate as Acne Drug Denifanstat Receives NDA Approval in China
Dec 10 2025
Newsfilter
Ascletis Submits NDA for Denifanstat, a Novel Acne Treatment
Dec 10 2025
Newsfilter
Ascletis Submits NDA for Denifanstat, a Novel Acne Treatment
Dec 10 2025
PRnewswire
Sagimet Biosciences Approves 42,800 Stock Options for New Hires
Dec 09 2025
Globenewswire
Sagimet Biosciences Grants 42,800 Stock Options to New Employees
Dec 09 2025
Newsfilter
Show More News
